Meet with… Sanderling Ventures

Apr 7 2016

Sanderling is investing in today's seeds for tomorrow's harvest; is your technology the next bumper crop?

Since 1979, Sanderling has been dedicated to building new biomedical companies, utilizing a unique approach of specialized investment focus, active managing and long term commitment. Sanderling has supported over 90 biomedical companies from very early stage start-ups, through commercial development.

Investments are made at all stages with a focus on ground breaking early stage technologies that reduce costs in hospitals. Currently they are investing Sanderling VII which closed in 2015. Investment areas include:

  • Vaccines
  • Drug delivery
  • Research tools
  • Platform technology
  • Medical devices
  • Diagnostics
  • Imaging agents/devices
  • Digital/eHealth

Sanderling Ventures Managing Director Timothy Mills will be in attendance to give an overview presentation about the company's key areas of interest. Following the presentation, don't miss this opportunity to introduce yourself to Timothy during the networking lunch. And finally, for those companies who apply online and are approved, one-on-one meetings with Sanderling will provide an intimate forum to discuss your company.

10:30am | Registration Opens and Networking
11:00am | Presentation and Q&A
11:45am | Networking Lunch
1:00-5:00pm | One-on-one Meetings*

*Companies must have applied for a one-on-one meeting ahead of time and be approved. The application period ends on March 9th, 2016.

Sanderling Ventures Participating Representative:
Timothy Mills Timothy Mills | Managing Director, Sanderling Ventures
Timothy Mills has over twenty-five years of experience in biomedical research, corporate management and venture capital investing. Dr. Mills joined Sanderling as an Operating Partner in July 1998, was promoted to Managing Director in 2000 and currently serves as the Chairman of the Investment Committee. At Sanderling, Dr. Mills has focused on early stage investments in Medical Devices, Biotherapeutics, and i-Health. His active roles within Sanderling's portfolio companies include Chairman, CEO, Director, and management team member. Portfolio companies previously served include Stereotaxis (NASDAQ: STXS), Stentor, acquired by Royal Philips Electronics (NYSE: PHG, AEX: PHI), CardioNet (NASDAQ: BEAT), Taligen Therapeutics, acquired by Alexion Pharmaceuticals (NASDAQ: ALXN), Neomend, acquired by C.R. Bard (NYSE: BCR), Sotera Wireless and InfraReDx (acquired by Nipro Corporation). Currently, his roles also include Chairman of Torax Medical, Pulsar Vascular and AdMIRx. Prior to joining Sanderling, Dr. Mills served as the Corporate Vice President of New Business Development and Chief Scientific Officer of Target Therapeutics, a medical device company that was acquired by Boston Scientific (NYSE: BSX) in 1997 for $1.3 billion. From July 1994 to July 1997, he was a Director for Prograft Medical, a Target affiliate that was acquired by W.L Gore & Associates. Before joining Target in 1994, Dr. Mills served as Director of Business Development and Advanced Research & Development in the Interventional Cardiology Division of Baxter Healthcare, now Edwards Life Science (NYSE: EW). Dr. Mills' previous academic appointments included Director of the Artificial Heart Program at the University of California, Irvine Medical Center and faculty member at the University of California, San Francisco Radiology Department. Dr. Mills received his Ph.D. in Bioengineering from the University of California, Berkeley & San Francisco School of Medicine. He also received a M.S. in Electrical Engineering & Computer Science from the University of California, Berkeley, and a B.S. in Electrical Engineering from the University of Colorado, Boulder. In addition, he is an advisory board member of the University of Colorado Technology Transfer Office and a program faculty member of the Stanford University Biodesign program.
Connect with Timothy: Connect on LinkedIn

Presentation & Lunch
$25 | General Public
$35 | General Public Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Registration to attend the presentation, Q&A, and lunch will remain open until April 6th, 2016 (or sold out).

One-on-One Meeting
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period ends on March 9th, 2016. Your application will be reviewed and you will be notified of acceptance by March 24th, 2016. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.

Johnson & Johnson Innovation, JLABS
329 Oyster Point Blvd - 3rd Floor
South San Francisco, California
Map It

About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCI, NCATS, NINDS, Allegory Venture Partners, Clarus Ventures, Johnson & Johnson Innovation, Poliwogg, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.